

EXHIBIT 4

(Part 1 of 2)



Prescription Drug User Fee Act III – Initiatives & Evaluations

Contract No. 223-04-8100 Task No. T1

**Independent Evaluation of FDA's First Cycle
Review Performance –
Retrospective Analysis Final Report**

January 2006

Prepared by Booz Allen Hamilton Inc.

TABLE OF CONTENTS

EXECUTIVE SUMMARY III

TASK OVERVIEW 1

METHODOLOGY AND ANALYSIS OVERVIEW 2

 Hypothesis/Metric Generation – Potential Drivers of Multi-Cycle Reviews 3

 Action Package Review – Quantitative and Qualitative Analysis 4

 Product Summary Validation 5

FINDINGS AND RECOMMENDATIONS 6

 Drug/Disease Characteristics 6

 Therapeutic Area, Medical Need and Novelty of Mechanism of Action 6

 Review Designation 7

 Drug Origin 8

 Advisory Committee Meetings 8

 Sponsor Characteristics 9

 The Review Process 10

 Product/Application Deficiencies 11

 Impact of Pre-Submission Meetings 12

 Issue Identification Timing and Resolution 15

 Communication Style and Timing 17

 Post-Marketing Commitments 24

 FDA Characteristics 27

 FDA Workload 27

 GMP Inspection Process 28

SUMMARY OF RECOMMENDATIONS 31

EXHIBITS

Exhibit 1. Action Package Approval Rate2

Exhibit 2. Overview of Analysis Process3

Exhibit 3. Drivers and Hypotheses of Multi-Cycle Reviews4

Exhibit 4. RPM Product Summary Comments5

Exhibit 5. Approval Rate vs. Novelty and Indication7

Exhibit 6. Approval Cycle Percentage by Application Type8

Exhibit 7. Approval Rate vs. Drug Origin8

Exhibit 8. Number of Approval Cycles as a Function of Advisory Committee Meetings9

Exhibit 9. Percentage of Multi-Cycle Reviews by Sponsor Experience9

Exhibit 10. Approval Rate vs. Sponsor Type and Origin10

Exhibit 11. Key Deficiencies Cited in Action Letter of Multi-Cycle Applications by Category11

Exhibit 12. Key Deficiencies Cited in Action Letter of Multi-Cycle Applications by Area12

Exhibit 13. FDA Meeting/Communication Perceptions and Practices12

Exhibit 14. Effect of End of Phase 2 Meetings on Approval Rate13

Exhibit 15. Effect of Pre-NDA/BLA Meetings and Timing on Approval Rate14

Exhibit 16. Pre-NDA/BLA Meetings and Issue Identification14

Exhibit 17. Resolution of Issues Identified Pre-submission15

Exhibit 18. Deficiency Timing in Multiple Cycle Applications16

Exhibit 19. Sponsor Resolution of Deficiencies16

Exhibit 20. Check-and-Follow Up Communication17

Exhibit 21. FDA-Sponsor Interaction Opportunities18

Exhibit 22. FDA Meeting Routine by Division19

Exhibit 23. FDA-Sponsor Communications20

Exhibit 24. Effect of Communication Style on First-Cycle Approval Rate21

Exhibit 25. Multi-Cycle Product Reviews Marked with Ineffective FDA-Sponsor Interaction21

Exhibit 26. Issue Resolution Timing – Multiple Cycle Applications **Error! Bookmark not defined.**

Exhibit 27. Issue Resolution Timing – Single Cycle Applications23

Exhibit 28. Review Communication Summary24

Exhibit 29. Post-Marketing Commitments Single vs. Multi-Cycle Reviews25

Exhibit 30. Focus and Burden of Post-Marketing Commitments25

Exhibit 31. Disposition of Significant First Action Deficiencies in Multi-Cycle Approvals26

Exhibit 32. Submission Timing vs. Number of Submissions or First-Cycle Approval Rates27

Exhibit 33. Submission Timing vs. Number or Type of Issues per Application28

Exhibit 34. Foreign or Domestic CGMP Inspection vs. % of Single or Multiple Review Cycles..29

Exhibit 35. Schematic of the CGMP Inspection Process and Improvement Opportunities29

Exhibit 36. Summary Overview of Recommendations31

EXECUTIVE SUMMARY

This report summarizes a retrospective analysis of factors affecting the FDA first cycle review of new drugs (NDAs) and biologics (BLAs). Several factors appear to be significant contributors to a multi-cycle review versus a first-cycle approval. Application quality and communication (between the FDA and sponsors, and FDA internal) emerged as having significant influence. Variations in FDA review practices across divisions may also be a factor, although these are, in part, driven by medical need and the specifics of therapeutic areas. Another potential factor contributing to multi-cycle reviews is the significant delay or lack of response from sponsors to concerns highlighted by FDA reviewers. This report suggests measures that can be adopted by the FDA and sponsors to increase review efficiency and communication effectiveness, which may lead to higher first-cycle approval rates.

Study overview

The study was comprised of all NME applications (77), submitted between FY 2002 and 2004 that had reached first action by December 1, 2004. The focus is on the management and procedures for FDA product reviews and is not intended to evaluate the merit of the underlying science or quality of discipline reviews. The primary sources of data are FDA-compiled product Action Packages which contain records of FDA internal and FDA-sponsor communications and review documents, as well as interviews with FDA review team members, division directors and members of the FDA senior leadership team. Gaining the perspectives of sponsors on the root causes for multi-cycle approvals was beyond the scope of this study. A planned prospective study will include an opportunity to solicit input from sponsors.

Of the 77 submissions (14 BLAs, 63 NDAs), 36 (47%) received first-cycle approval, 18 (23%) were approved in multiple cycles and 22 (30%) were still pending at the time of analysis. Drivers of multi-cycle reviews were found to include product characteristics, sponsor characteristics, quality of the design and execution of the drug development program, variations in review processes, and development of post-marketing commitments.

Drug/Disease characteristics

Priority and Fast-Track products have higher first-cycle approval rates. Beyond the unmet medical need however, increased regulatory and sponsor attention throughout the drug development and review process may contribute to the timely identification and resolution of issues.

Sponsor characteristics

The degree of sponsor experience with FDA regulations and procedures is generally of importance. Large US-based companies have the highest first-cycle approval rate, at approximately twice the rate of small biotechnology companies with no prior FDA approvals. The underlying drivers seem to be lack of personnel with US regulatory experience and suboptimal sponsor-internal regulatory processes. The FDA can actively aid these sponsors by dedicating resources to education programs emphasizing critical drug development/regulatory requirements, updating and streamlining the portfolio of guidances, and proactively directing sponsors to these guidances.

Drug development program

Most products that fail to receive first-cycle approval have key deficiencies in only one or two categories, with an even breakdown between the categories of safety, efficacy, and chemistry (includes manufacturing related issues). There is also no single dominant cause, with the basis

for the deficiencies falling evenly across development program design, execution, and failure to meet endpoints.

FDA reviewer team members agree that early on-going dialog with sponsors is the most important factor in identifying issues and potentially providing an opportunity for timely resolution, ideally before first action is taken. All divisions interviewed routinely strive to start discussions with the sponsors before the submission. These efforts meet with mixed success: End-of-Phase 2 meetings appear to significantly contribute to first-cycle approval while Pre-NDA/BLA meetings had a lesser impact. In some instances, substantial deficiencies were not documented/identified until the review phase, potentially preventing first-cycle approval despite the possible availability of pertinent information at the time of Pre-BLA/NDA meetings. This finding may be attributed to the general focus of these meetings on application formatting rather than review of development results. When issues are identified, there is often insufficient time to adequately address these as submission timelines are generally not delayed. This may be due to sponsors' unwillingness to adopt FDA suggestions or a lack of clarity in FDA communications on the severity of the issues raised. There are also examples where sponsors are able to resolve issues via a different path than originally recommended by the FDA. These findings point to broad issues around coverage of problem areas prior to submission, ineffective communication between the FDA and sponsors, and unclear prioritization of issues and/or problem resolution requirements.

An approach to address this challenge is the development of an open and accountable communication system centered around issue resolution. This system may include a pre-submission check-list and follow-up responsibilities that will guide FDA-Sponsor discussions and ensure that these communications are better leveraged to achieve agreement on issue resolution. This system – termed in this report as check-and-follow up communication – will increase consistency and reduce the risk of overlooking key issues at pre-submission stages.

Application review under PDUFA

Broad variations were observed in the frequency and timing of communications throughout the review. However, there was no systemic difference with respect to these parameters between single vs. multi-cycle approvals. Nevertheless, effective communication and responsiveness to FDA inquiries marked first-cycle approvals while persisting disagreements over issue resolution were associated with approval delays. Additionally, there were instances of multi-cycle approvals where earlier FDA communication of major issues may have possibly led to resolution within the first-cycle.

The recently introduced Good Review Management Principles and Practices (GRMPs) guidance recommends specific timelines for NDA/BLA review procedures. These along with additional structured communications within the review team and with sponsors recommended in this report could ensure a more productive review. Further, early and open communication with the sponsors will allow sponsors to address/resolve issues in a timely manner, potentially within the first review cycle.

Post-marketing commitments

There is broad variability in the use of post-marketing commitments (PMCs) and a lack of guidelines for PMC development. Most approvals have post-marketing commitments, with no significant difference between single and multi-cycle approvals in the average number, focus, and burden of commitments. A number of products approved in multiple review cycles had certain deficiencies in the first action letter that remained unresolved in the second review and

were included as post marketing commitments in the approval letter. A guide for post-marketing commitments will introduce transparency, facilitate discussions, help sponsors prioritize deficiencies and help guide sponsor's development plans, ultimately improving the quality of submissions.

FDA characteristics

The FDA receives between two and three times the number of submissions in the fourth quarter compared to any other quarter in the calendar year. These applications have the lowest rate of first-cycle approvals. High-level metrics show no difference in the quality of these applications compared to submissions in other quarters, suggesting potential FDA staff workload issues. A deeper analysis quantifying FDA workload is however, necessary to better establish the underlying drivers and identify improvement opportunities.

The manufacturing facility inspection process is often considered a potential bottleneck in meeting PDUFA clock goals and the cause of multi-cycle reviews. A cursory mapping of this process suggests that the current system does not offer sufficient flexibility to complete inspections early on to enable problem rectification within the review cycle. This is further exacerbated in instances where foreign inspections are required, and/or review times are compressed due to, for example, Priority status of applications. Earlier involvement of CDER Consumer Safety Officers (for example, at pre-NDA stages) is recommended to foster better planning and mitigate risks¹. Although this practice will not necessarily, in all instances, enable a complete resolution of facility issues within the first-cycle, it will provide a better opportunity for the sponsor to input a genuine effort. Furthermore, a closer review of the current processes for inspection team notification and scheduling can potentially yield measures whereby the inspection process can be streamlined, reducing the overall inspection time, and ultimately time to market for new products.

A number of the suggested recommendations may have resource implications for the FDA and sponsors. Quantification of the specific resource needs was beyond the scope of this project. However, the expected improvements to the review process, increased rate of first cycle approvals, and over time, the implied reduction in duplicative efforts from multi-cycle reviews may off-set the additional resource needs. An increase in resources is expected for the initial implementation phase, during which the benefits of the improved process have not yet been realized.

¹ CBER has incorporated this concept into its BLA review process; CBER Consumer Safety Officers participate in pre-BLA meetings.

TASK OVERVIEW

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA) authorizing revenues from fees paid by the pharmaceutical industry. These revenues provide the Food and Drug Administration (FDA) with additional resources and allow the FDA to expedite and improve the review of human drug applications.

PDUFA is renewed every five years. Currently in its second renewal (PDUFA III), the FDA has committed to achieving specific performance goals to improve the effectiveness and efficiency of NDA and BLA reviews. Several of these goals are aimed at improving the portion of the review process that occurs between the initial submission of the application and subsequent FDA action (i.e., the first review cycle).

The PDUFA III goals specify that the FDA will retain an independent expert consultant to evaluate the review process improvement initiatives and the impact of the Good Review Management Principles (GRMP) initiative. The FDA has contracted Booz Allen to perform an independent program evaluation of the product review process. The primary goal of the overall evaluation is to determine the impact of the FDA's implementation of initiatives to enhance first-cycle review performance of New Molecular Entities (NMEs) during the five-year period of PDUFA III.

Under this task, the evaluation will consist of a retrospective analysis focused on the review processes that are conducted on NME NDAs and BLAs. This report highlights findings from Booz Allen's first task-order, a retrospective study of all NMEs submitted during PDUFA cohort fiscal years – 2002 to 2004 that have reached first action by December 1, 2004.

METHODOLOGY AND ANALYSIS OVERVIEW

Action packages were analyzed relating to all NME NDAs and BLAs submitted during fiscal years 2002-2004 that reached first action by December 1, 2004 (77 applications in total). Action Packages are typically a compilation of product review documents (e.g., discipline review letters and review meeting minutes) and, in some instances, pre-submission documents (e.g., pre-NDA/BLA meeting minutes). These packages generally contain the critical information required for Office and/or Division Directors to formulate the action (Approval, Approvable, or Not Approvable²). Action packages were not, however, specifically developed for the purposes of this retrospective study and content gaps were encountered. Where feasible, input from FDA Regulatory Project Managers (RPMs) involved in the product review was solicited to fill in missing information. The study was not intended to evaluate the merit of the underlying science or quality of discipline reviews, but rather to investigate process issues that may drive multiple review cycles. Finally, this analysis is solely based on data originating from the FDA. A planned prospective study will also aim to capture sponsor perspectives and data.





Exhibit 1 depicts the breakdown of the action packages used in the study with respect to review outcomes. The key focus of the activity was to understand:

- ▶ Characteristics and best practices promoting first-cycle approval
- ▶ Drivers/lessons learned from multiple cycle approvals
- ▶ Overall improvement opportunities for the FDA and sponsors

A two-staged approach was followed, as depicted in Exhibit 2:

² The Center of Biologics Evaluation and Research (CBER) uses correlated terms of Approved, Complete Response, and Not Approved

Exhibit 2. Overview of Analysis Process




The first stage was comprised of generating hypotheses of potential multiple cycle review drivers and the appropriate metrics. To test these hypotheses, action packages were reviewed and information relevant to the metrics was captured in data collection instruments (DCIs). Word summaries of each product were also created reflecting important regulatory events and key drivers of multiple cycle reviews or, in the case of single cycle approvals, best practices. The DCIs and word summaries were used to drive qualitative and quantitative analysis of the potential drivers of multiple cycle reviews. The results of these analyses were used to synthesize emerging themes and recommendations in the final activity of this stage.

In the second stage, findings and recommendations were reviewed with FDA Regulatory Project Managers (RPMs) for validation. Additionally, divisional philosophies and best practices were captured and used to validate and expand on the themes and recommendations formulated in the first stage.

Hypothesis/Metric Generation – Potential Drivers of Multi-Cycle Reviews

Exhibit 3 shows a sample set of metrics and hypotheses developed in conjunction with FDA reviewers³:

³ Exhibit 3 only displays four sample hypotheses taken from a comprehensive list of 62

Exhibit 3. Drivers and Hypotheses of Multi-Cycle Reviews**Action Package Review – Quantitative and Qualitative Analysis**

A typical action package may contain the following elements:

- ▶ Action Letter(s)
- ▶ Discipline Reviews (Chemistry, Medical, Labeling, CMC, and Consults)
- ▶ Correspondence from the FDA to Sponsor (Letters and Faxes)
- ▶ Internal FDA correspondence (Emails and Inspection results)
- ▶ Meeting notes

For each of the 77 products, data on common variables were recorded into DCIs for analysis across the broad array of products. These formed the basis of the quantitative analyses (see section on Findings and Recommendations). The captured information included:

- ▶ Clock and goal dates
- ▶ Review team members
- ▶ Requests for information and timing
- ▶ Nature of the issues raised
- ▶ Timelines for responding to communications and information requests

Publicly available data sources were used to supplement product and sponsor company background information including:


- ▶ Novelty of mechanism of action
- ▶ Sponsor profiles (e.g., previous experiences with FDA)

Product Summary Validation

A sample of approximately one third (23 out of 77) of the Action Package Product Summaries was selected for validation by the respective RPMs, verifying the accuracy of Booz Allen analysis. Products were selected such as to minimize the impact on RPMs (i.e., RPMs involved with multiple products in the cohort were selected over RPMs with only one product assignment) and to represent a variety of review divisions. In general, RPMs agreed in all instances with the assessment of the critical issues and product review analyses. Changes were minor and included comments on the background information on sponsors, products and submissions (Exhibit 4).

Exhibit 4. RPM Product Summary Comments

**Product Summary Validation
(Review of 23 Action Packages*)**



() 23 (approximately 1/3 of the cohort) product summaries reviewed with regulatory project managers; for accuracy*

FINDINGS AND RECOMMENDATIONS

The hypotheses that were tested were grouped under four key characteristics of multiple cycle reviews:

- ▶ Drug/Disease Characteristics
- ▶ Sponsor Characteristics
- ▶ Review Process Characteristics
- ▶ FDA Characteristics

A statistical analysis was not feasible due to the low number of applications in the cohorts. In some instances, the number of product applications meeting the test criteria was even further limited (for example, novel mechanism of action coupled with product origin: in-house vs. acquired technology), potentially impacting the ability to generalize conclusions.

Certain product designations such as the Drug Efficacy Study Implementation (DESI) program or 505 (b)(2) significantly alter filing requirements. The DESI program applies to drugs approved before 1962 solely on the basis of safety. Depending on product characteristics, the sponsor of a DESI application may be only responsible for demonstrating efficacy. Extraneous demands (e.g., for counterterrorism or to address drug shortages) led the FDA to initiate its own effort to collect and evaluate safety/efficacy data and issue Federal Register notices for applications under the 505(b)(2) designation. As a result, these applications are primarily focused on manufacturing. Both DESI and 505(b)(2) applications were excluded from most analyses as a result of their non-standard content.


Drug/Disease Characteristics

The impact of drug/disease characteristics on first-cycle approval rate was categorized by therapeutic area, medical need, novelty of the mechanism of action, review designation and drug origin.

Therapeutic Area, Medical Need and Novelty of Mechanism of Action

As a product class, novel drugs targeting acute, life threatening conditions have the highest rate of first-cycle approval (73%) compared to either criteria alone (40% for life-threatening and 64% for novel mechanism of action; see Exhibit 5). Non-novel products for non-life threatening conditions had the lowest first-cycle approval rate with 28%. These findings are not unexpected given the severity of the medical conditions addressed, the different levels of acceptable risk and the urgency for new therapies. However, other factors may also be contributing as interviews with FDA reviewers suggest that novel drugs for which limited and/or ineffective therapy choices are available receive greater attention from the FDA and sponsors. Extensive effort is placed on completing reviews of these drugs within six months, regardless of their priority status, and division directors proactively align resources to support expedited reviews. Conversely, for products for which alternative therapies are available, sponsors may forego potential drug development meetings and the division director involvement may come later in the review.

Exhibit 5. Approval Rate vs. Novelty and Indication




Note: Not Including DESI, 505(b)(2) drugs

Review Designation

Fast-Track/ Rolling and Priority review status are used to expedite the drug development and review processes of products addressing diseases with significant unmet medical needs. For products with these designations, the FDA may engage in more pre-submission communications with sponsors, and review applications in six months. Orphan drug and Fee-Waiver designations provide for financial incentives to small companies and those developing drugs for rare indications but do not impact the review process per se. The Fast-Track and Priority review programs seemed effective in driving single cycle approvals as 62% of drugs (16 of 26) with Priority status received first-cycle approval compared to only 34% for non-priority drugs (Exhibit 6a). Similarly, high first-cycle approval rates were observed for Fast-Track products. Orphan drug and Fee-Waiver designations however, did not lead to similar outcomes with only 33% and 12% first-cycle approval rates, respectively (Exhibit 6b). Notably, many Orphan designated products also merited a Fast-Track and/or Priority review designation. No difference was seen in the first-cycle approval rate between Orphan and Fast-Track versus Orphan without Fast-Track status. Of the Priority applications, six also had Orphan status with three of these applications achieving first-cycle approval (50%). Of the 19 remaining Priority applications, 12 (63%) achieved first-cycle approval. A lack of sponsor's regulatory experience may be a compounding factor for the Orphan and Fee-Waived application first-cycle approval rates, since most of the products with these designations were developed by small companies with previously no approved products (see section on Sponsor Characteristics).

Exhibit 6. Approval Cycle Percentage by Application Type




P = Priority designated applications
 Notes: Not including DESI, 505(b)(2) drugs
 Source: BAH Analysis

Drug Origin

Further supporting the significance of increased focus, greater sponsor diligence may be contributing to the higher success of externally sourced (in-licensed) products, compared to those originated in-house (Exhibit 7). This may arise from the increased scrutiny that products may be exposed to at the selection phase and/or closer attention paid by sponsors during drug development.


Exhibit 7. Approval Rate vs. Drug Origin



Advisory Committee Meetings

First-cycle approval rates were slightly lower for products for which input from Advisory Committees was solicited (Exhibit 8). This is consistent with the notion that such meetings are generally requested for products with significant unknowns or controversial issues.


Exhibit 8. Number of Approval Cycles as a Function of Advisory Committee Meetings



Sponsor Characteristics


Sponsor experience with the FDA approval processes appears to contribute to first-cycle approvals. The first-cycle approval rate for sponsors that had drugs approved previously by the FDA was 51% compared to 30% for sponsors with no prior approved drugs (Exhibit 9a). Experience within the specific therapeutic area however, did not seem to have an additional effect (Exhibit 9b).

Exhibit 9. Percentage of Multi-Cycle Reviews by Sponsor Experience



Consistent with the importance of experience, larger and US-based sponsors are more likely to gain first-cycle approval (64% and 86% for US-based large pharmaceutical and biotechnology companies, respectively; see Exhibit 10). On the other hand, inexperienced drug developers (generally small biotechnology companies without prior US-approved products) had the lowest first-cycle approval rate (33%).

Exhibit 10. Approval Rate vs. Sponsor Type and Origin



According to FDA reviewers, unfamiliarity with FDA regulations and the drug application process is a key problem for inexperienced sponsors and results in poor quality submissions. In the case of foreign companies, language barriers as well as communication styles, which can be less formal in other countries, may also be an issue.

Sponsor-side improvement opportunities may involve complementing teams with experienced regulatory consultants or leveraging clinical research organizations (CROs) experienced with FDA processes for submissions. Additionally, inexperienced sponsors would likely benefit from improving communications. These improvements include engaging in early and open dialog employing FDA-preferred methods (e.g. appropriate forms and correct submission procedures), and developing processes to rapidly respond to FDA requests.

The FDA can facilitate these processes by targeting less experienced sponsors with workshops and updated and streamlined guidance portfolios, as well as improving the utility of the website which includes sections targeted to these sponsors. Implementing and maintaining these recommendations may require additional FDA resources. These resource needs could be offset, in the long-term, by reducing the incidence of multiple cycle reviews. An in-depth analysis into workload duplicities is necessary to quantify the cost vs. benefit (savings).


The Review Process

The impact of regulatory review processes and interactions between FDA and sponsors during the clinical development phase (i.e., pre-submission) and the review phase on the first-cycle approval rate were assessed. Variables included the timing and frequency of meetings, timing and effectiveness of communication of application issues, timing of manufacturing inspections, etc. Not all action packages contained comprehensive documentation of all pre-submission events. However, more significant milestone meetings (such as End of Phase 2) were generally included and these comprised the basis for the pre-submission analyses.

Product/Application Deficiencies

The majority of multi-cycle applications have significant deficiencies in only one or two key categories (Exhibit 11). A "significant" deficiency is defined as a product or application related issue that would prevent first-cycle approval if not adequately addressed. Of the 37 applications requiring multiple cycles, 20 were cited for a single significant deficiency in the safety, efficacy or CMC categories. Nine applications failed due to deficiencies in a combination of two of these categories and two for a combination of application format and either CMC or safety. The six remaining multiple cycle applications failed with significant deficiencies in more than two categories. The overall distribution of the issues was fairly evenly divided between safety and efficacy (20 and 17, respectively) with CMC issues trailing only slightly (12) and a relatively small number of submission format issues.


Exhibit 11. Key Deficiencies Cited in Action Letter of Multi-Cycle Applications by Category



Notes: (1) Not Including DESI, 505(b)(2) drugs

The origin of these deficiencies, in turn, is expected to fall in the areas of design (e.g. of the trial or manufacturing process), execution (e.g. unacceptable clinical execution), or failure to meet study objectives (e.g. clinical endpoints) (Exhibit 12). Of the 61 significant deficiencies cited in 37 first action letters, 17 related to trial design, 15 to execution and 23 to endpoints. The remaining six application format deficiencies were related to inconsistent documentation or record keeping, inability to locate information or failure to translate from foreign languages into English.

Exhibit 12. Key Deficiencies Cited in Action Letter of Multi-Cycle Applications by Area



Note: Not Including DESI, 505(b)(2) drugs

Impact of Pre-Submission Meetings

Review team members generally consider open and frequent communication as having a high impact on the review process (Exhibit 13a). All divisions interviewed frequently engage in both End of Phase 2 (EOP2) and Pre-NDA/BLA meetings in an attempt to identify issues early, thereby maximizing the time and potential for problem resolution – ideally before the first review is completed (Exhibit 13b.).

Exhibit 13. FDA Meeting/Communication Perceptions and Practices

a. Perceived Impact of Common Review Factors

| Review Factor | Perceived Impact on Review |
|--|----------------------------|
| Pre-submission Interaction / Knowledge | High |
| RPM experience / knowledge in drug class or therapeutic area | Moderate |
| RPM Workload | Moderate |
| Division Workload | Moderate |
| FDA Internal communication | High |
| FDA-Sponsor communication | High |
| FDA-Sponsor relationship | Moderate |

Legend: ● High, ◐ Moderate, ○ None

*Based on interviews with 15 RPMs, 8 Reviewers and 7 Division Directors

b. Meeting Routine Pre-Submission


| Division | Pre-IND | EOP2 | Pre-NDA/BLA |
|----------|--------------|------------|-------------|
| A | Frequently | Frequently | Frequently |
| B | Occasionally | Frequently | Frequently |
| C | Occasionally | Frequently | Frequently |
| D | Occasionally | Frequently | Frequently |
| E | Rarely | Frequently | Frequently |
| F | Frequently | Frequently | Frequently |
| G | Occasionally | Frequently | Frequently |
| H | Occasionally | Frequently | Frequently |

Legend: ● Frequently, ◐ Occasionally, ○ Rarely

Pre-IND – Pre-IND meeting or interaction
EoP2 – End of Phase 2 meetings
Pre-BLA/NDA – Generally ~6 months pre-submission

EOP2 meetings have a positive impact on first-cycle approval rate. Of 46 products with EOP2 meetings, 52% received first-cycle approval, vs. only 29% for products that did not have such meetings (Exhibit 14a). However, there seems to be room for improvement: of the multiple-cycle applications that had an EOP2 meeting, 25% of these applications had the critical issue preventing first-cycle approval identified at this meeting, indicating a failure or an inability by the sponsor to resolve problems prior to submission (Exhibit 14b). Further analysis is required to establish whether there was also an opportunity to identify the remaining deficiencies of these multi-cycle applications at the EOP2 stage (36% were identified at the pre-NDA/BLA meeting and 41% during the review).


Exhibit 14. Effect of End of Phase 2 Meetings on Approval Rate




Pre-NDA/BLA meetings, while important, do not appear to have as beneficial an effect on first-cycle outcome as EOP2 meetings. Products with pre-NDA/BLA meetings had a first-cycle success rate of 47% compared with 33% for products without such meetings (Exhibit 15a). This finding is not affected however, by the timing relative to the submission (Exhibit 15b).

Exhibit 15. Effect of Pre-NDA/BLA Meetings and Timing on Approval Rate

a. Pre-NDA/BLA Meeting



b. Timing of Pre-NDA/BLA Meeting



Note: Not Including DESI, 505(b)(2) drugs

Consistent with the above finding, interviews revealed that the content of the pre-NDA/BLA meeting is generally regarded as administrative, with a focus on application format considerations. In fact, there are many examples in which analysis of communications in action packages indicates that pre-NDA/BLA meetings fail to uncover major issues that contributed to multi-cycle reviews (Exhibit 16). In many of the cases illustrated, the relevant information should have been available at the time of the meeting and the subject matter fell within the boundaries of topics that can be covered at such meetings.

Exhibit 16. Pre-NDA/BLA Meetings and Issue Identification

| Product * | Major Issues Not Addressed at Pre-NDA/BLA Meeting | Data Available at Pre-NDA/BLA? | FDA Action That May Have Promoted Earlier Issue Identification |
|-----------|--|---|---|
| Product A | <ul style="list-style-type: none"> ▶ Variations in clinical trial designs produced conflicting results ▶ Unclear organization of safety data files resulted in discrepancies ▶ Errors and inconsistencies in AE coding ▶ Inadequate preclinical data | <ul style="list-style-type: none"> ✓ ✓ ✓ ✓ | <ul style="list-style-type: none"> ▶ Preview of all pivotal clinical protocols and data ▶ Further discuss the proposed formats at Pre-NDA/BLA meetings ▶ Review complete pharm/tox studies; request preclinical data |
| Product B | <ul style="list-style-type: none"> ▶ Unacceptable manufacturing facility | ? | <ul style="list-style-type: none"> ▶ Access prior FDA inspection reports |
| Product C | <ul style="list-style-type: none"> ▶ High tumor incidence in animal studies | ✓ | <ul style="list-style-type: none"> ▶ Review preclinical data and/or ask for appropriate data |
| Product D | <ul style="list-style-type: none"> ▶ Missing sub-population information ▶ Inappropriate primary endpoint ▶ Unclear criteria for clinical positive assessment ▶ Missing information in the AE database ▶ Inadequate analysis of AE events | <ul style="list-style-type: none"> x ✓ ✓ ✓ ✓ | <ul style="list-style-type: none"> ▶ Level of detail beyond the scope of pre-NDA meetings ▶ Agree on clinical trial design and endpoints ▶ Confirm guidelines for AE capture and reporting |
| Product E | <ul style="list-style-type: none"> ▶ Manufacturing contamination | ? | <ul style="list-style-type: none"> ▶ Review prior FDA inspection reports |
| Product F | <ul style="list-style-type: none"> ▶ Missing stability data; inappropriate validation methods ▶ Discrepancies in AE description | <ul style="list-style-type: none"> ✓ ? | <ul style="list-style-type: none"> ▶ Provide relevant guidance Pre-NDA/BLA meeting ▶ Confirm guidelines for AE capture and reporting |

Legend:



- ✓ = Information likely available pre-NDA to identify the issue
- x = Information not likely to have been available pre-NDA
- ? = Unknown

(*): Multiple review cycles products with no major pre-BLA/NDA issue

Source: BAH Analysis

Issue Identification Timing and Resolution

Even when major deficiencies are identified in pre-submission meetings, sponsors do not always address them prior to submission. Seventy-one percent of applications with key issues identified during the pre-submission phase had not resolved these issues by first action (Exhibit 17a). Issues around safety and efficacy saw the lowest rate of resolution by first action (Exhibit 17b) potentially reflective of the generally more difficult and time-consuming nature of these issues.

Exhibit 17. Resolution of Issues Identified Pre-submission**a. Percent of Applications with Significant Pre-Submission Issues Resolved by First Action****b. Percent of Applications with Significant Issues Identified Pre-Submission and Resolved by First Action**


*Pre-submission meetings identified major issues in 24 products -- in some cases, >1 major issue was identified; 17 drugs required >1 review cycle for approval
Source: BAH Analysis*

In many cases, sponsors were informed of key deficiencies well in advance of the submission date. As shown in Exhibit 18, despite this early communication, sponsors do not always resolve these issues prior to submission. There are conceivably a number of explanations that can lead to this outcome:

- ▶ A lack of clarity on the severity of issues communicated by the FDA
- ▶ Differences in opinion, and sponsors' belief that the issues can be resolved during the review
- ▶ Sponsor's unwillingness to comply with FDA requests, which in some instances would also require postponing submissions to allow for sufficient resolution time
- ▶ Sponsor's interest in receiving a comprehensive review of all elements of the applications to highlight any additional deficiencies and address these all after the first action

Under the first two scenarios, ensuring a common understanding of the severity, and agreeing on a plan forward can help postpone submissions until such time that issues are adequately addressed. In the latter two cases, multi-cycle reviews will be difficult to avoid if the applications are accepted for filing by the FDA. A more detailed analysis with input from the sponsors is necessary to establish the underlying drivers in each instance.

Exhibit 18. Deficiency Timing in Multiple Cycle Applications



In some cases, sponsors and the FDA are able to reach alternative resolutions to important pre-submission issues and gain first-cycle approval. These for example, included working with the FDA to salvage trials that had to be supplemented after initiation, or modifying or unbundling indications to pursue subgroups of the initially targeted patient population (Exhibit 19). This finding points to the importance of early and open discussions on acceptable resolution paths.

Exhibit 19. Sponsor Resolution of Deficiencies

| Product* | FDA Issue/Request | Comment |
|-----------|---|---|
| Product I | ▶ FDA advised sponsor that European Pharmacopoeia methods are not acceptable | ▶ Sponsor did not update methods; committed to transition to US methods post-approval |
| Product J | ▶ FDA proposed a new trial due to deviations from the accepted clinical protocol | ▶ FDA and sponsor agree on approach to salvage on-going trial |
| Product K | ▶ Concern that standard regimens not equivalent to existing therapies | ▶ Sponsor changes application from 1 st to 2 nd line regimen |
| Product L | ▶ Efficacy questions around specific populations; FDA requested sub-population analyses | ▶ Application unbundled based on indication, salvaging approval for sub-population with greatest efficacy |

(*): Single-cycle approved products with major pre-submission issue(s) not addressed by time of approval